Louis Theroux has released a new statement updating fans on his ongoing battle with alopecia. The BBC documentarian has been ...

Alopecia areata incidence was highest in patients in North America, Southeast Asia, and Australia, as well as in women and those aged 30 to 34 years.

Louis Theroux has revealed he is preparing for a "full head shave" due to his battle with alopecia.   The broadcaster, 54, ...

A new study has identified a protein that appears to be essential for hair growth and hair follicle protection. Called MCL‑1, it could potentially be targeted by treatments for certain kinds of ...

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study ...

(5) Alopecia Areata & Prediabetes: A large population-based study published recently in 2025 analyzed 33,401 Alopecia Areata patients and 66,802 controls, revealing a higher prevalence of prediabetes ...

Alopecia areata is an autoimmune disorder in which the immune system attacks hair follicles, leading to their inflammation and consequently to hair loss and impaired hair growth. The condition ...

Get Instant Summarized Text (Gist) Ivarmacitinib, a selective JAK1 inhibitor, is effective and tolerable for adults with severe alopecia areata at doses of 4 mg and 8 mg. In a phase 3 trial, 34.9% ...

ORLANDO, FLA. — Janus kinase (JAK) inhibitors have revolutionized the treatment of alopecia areata (AA), and more drugs in this class are still in development for AA. However, a new therapy with ...

Long-term ritlecitinib was generally well tolerated among patients aged 12 years and older with alopecia areata and showed clinically meaningful efficacy through 3 years. Treatment with ritlecitinib ...

Patients with severe to very severe alopecia areata saw hair regrowth with bempikibart treatment within 24 weeks. Hair regrowth seemed to persist after treatment cessation to week 36. ORLANDO ...

placebo in adults with severe alopecia areata, according to phase 3 data presented here. Oral ivarmacitinib significantly induced hair regrowth at 24 weeks compared with placebo in adults with ...